Q3 2025 Management View CEO Leonard Schleifer reported "double-digit net sales growth for 3 of our leading products," ...

Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter results on Tuesday, helped by strong demand for its ...

Over the last few months, as Len just mentioned, we have delivered multiple important data readouts, showcasing the strength of our robust pipeline and the potential to drive future growth with ...

Biotech company Regeneron (NASDAQ:REGN) reported Q3 CY2025 results , but sales were flat year on year at $3.75 billion. Its ...

Despite the rejection, analysts saw Regeneron’s use of an alternate filler for Eylea HD as a positive development, with BMO Capital Markets noting that this could signal the end of manufacturing ...

After news broke last weekend that President Donald Trump tested positive for COVID-19, Regeneron CEO Leonard Schleifer ’73 was once again thrust into the spotlight, running the biotech company ...

“I expect this to substantially increase the sales,” Regeneron CEO Leonard Schleifer, MD, PhD, told Reuters. 4. Express Scripts will share a portion of the rebates it receives for Praluent with ...

(Reuters) -Regeneron topped Wall Street estimates for second-quarter results on Friday, on robust demand for its blockbuster eczema drug Dupixent, and said it does not expect a material impact from ...

Regeneron Pharmaceuticals and 15 current and former executives and directors were hit with a shareholder derivative lawsuit on Sept. 2 in New York Supreme Court for Westchester County. The action, ...

Only 24 CEOs on the 2025 Fortune 500 list are founders or co-founders of the companies they lead. That amounts to just 4.8% of the index. Yet this small group commands outsized influence. Collectively ...

Q3 2025 Earnings Call Transcript October 28, 2025 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS ...